Authors of a paper share their perspectives on the topic of chronic pain in individuals with mental health disorders.
The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.
Polygenic risk scores predict the progression from unipolar depression to bipolar or psychiatric disorders.
Depression has been linked to elevated markers of inflammation, and aspirin, a nonsteroid, anti-inflammatory medication, can irreversibly inhibit cyclooxygenase-1 and 2.
Convergent abnormalities were observed in secondary analyses across portions of the amygdala, hippocampus, subgenual cingulate cortex, and putamen.
While the relationship between current mood state and cognitive impairment is unclear, more severe depression has been linked to greater impairment.
The researchers concluded that the correlation between interregional cortical thinning during maturation and expression patterns of genes associated with multiple psychiatric disorders suggested a common molecular process.
Alzheimer's Disease and Dementia
The FDA has granted Breakthrough Therapy designation to AXS-05 (Axsome Therapeutics) for the treatment of Alzheimer disease agitation.
Investigators posit that wearable devices will help psychiatrists to target mood and cognitive interventions.
The degree of overlap between MDD and burnout is unclear. However, dysfunctional sleep patterns are known risk factors for both conditions.